Observational studyBMC cancer2026
Routine biomarkers map response probability in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPathologic complete response (pCR) after neoadjuvant chemotherapy and dual HER2 blockade is associated with improved outcomes in HER2-positive breast cancer, but treatment response remains heterogeneous. We aimed to develop and externally validate an interpretable model based on routine clinicopathological biomarkers to predict pCR and identify clinically meaningful response states.
methodsIn this multicenter retrospective study, 1,082 patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade at two Chinese centers were included for model development and internal validation. An independent cohort of 307 patients from a third center was used for external validation. Machine-learning models were developed using routinely available pretreatment clinicopathological variables. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC). Probability-landscape analyses were performed to characterize biomarker-defined response states associated with pCR.
resultsThe final gradient boosting machine model achieved AUCs of 0.78 in internal testing and 0.70 in external validation. Probability-landscape analyses identified distinct response states with substantially different pCR probabilities. Low hormone receptor expression combined with HER2 immunohistochemistry (IHC) 3 + status defined a high-probability pCR state, whereas high hormone receptor expression, low Ki-67 expression, and HER2 IHC 2+/fluorescence in situ hybridization (FISH)-positive disease defined persistently low-probability states. Among baseline node-positive patients who achieved breast pCR, residual nodal disease was observed in only 6.1% of cases.
conclusionsRoutine clinicopathological biomarkers can be integrated into an interpretable machine-learning model to predict pCR and enable scalable response probability mapping in HER2-positive breast cancer receiving neoadjuvant chemotherapy and dual HER2 blockade. This approach may facilitate individualized treatment selection and support future treatment-adaptation and surgical de-escalation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.